CALGARY -- A Calgary-based drug maker successfully posted promising phase one trial results for its own COVID-19 vaccine, but the company’s future endeavours in Canada remain a question mark without federal funding for manufacturing. Providence Therapeutics released results Wednesday from 60 participants aged 18 to 64 that participated in the trial, which show “strong virus neutralization capability,” with no serious side effects reported. Participants received either a placebo or the PTX-COVID19-B vaccine made by Providence in one of three dose sizes. After 28 days, participants given any of the vaccine sizes showed COVID-19 antibodies, while all doses showed 100 per cent COVID-19 “blocking activity” after 42 days.